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Abstract
Aims: To investigate the effectiveness of sodium-glucose co-transporter-2 (SGLT2)
inhibitors on the risk of progression to end-stage renal disease (ESRD) and all-cause
mortality in a broad range of patients with type 2 diabetes (T2D) using a Korean
nationwide cohort.
Materials and Methods: Using data from the Korean National Health Insurance Ser-
vice database from January 2014 to December 2017, a total of 701 674 patients
were identified with T2D. We divided these patients into new users of SGLT2 inhibi-
tors and new users of other glucose-lowering drugs (oGLDs). Using propensity
scores, patients in the two groups were matched 1:1. We assessed the risk of ESRD
and all-cause death.
Results: There were 45 016 patients in each group, and baseline characteristics were
well balanced between the groups. The patients' mean age was 58.1 ± 10.6 years
and mean estimated glomerular filtration rate (eGFR) was 89.2 ± 27.4 mL/min/1.73m2,
and 8% of patients had proteinuria. We identified 167 incident ESRD cases and 1070
all-cause deaths during follow-up. Use of SGLT2 inhibitors versus oGLDs was associ-
ated with a lower risk of ESRD (hazard ratio [HR] 0.47, 95% confidence interval
[CI] 0.34 to 0.65) and all-cause death (HR 0.82, 95% CI 0.73 to 0.93). In a subgroup
analysis by eGFR, initiation of SGLT2 inhibitor treatment, compared with oGLD treat-
ment, was associated with lower risk of progression to ESRD among patients with
eGFR 60 to 90 mL/min/1.73m2 and those with eGFR < 60 mL/min/1.73m2, and a
lower risk of all-cause death was associated with SGLT2 inhibitors versus oGLDs in
patients with eGFR ≥90 and 60 to 90 mL/min/1.73m2.
Conclusion: In this large nationwide study of Korean patients with T2D, initiation of
SGLT2 inhibitors versus oGLDs was associated with lower risk of ESRD and all-cause
death.
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1 | INTRODUCTION
Diabetic nephropathy ranks highest, both globally and nationwide in
Korea, among causes of end-stage renal disease (ESRD), and its inci-
dence is growing exponentially.1 However, no new medications had
been approved for the treatment of diabetic kidney disease since the
IDNT (Irbesartan in Diabetic Nephropathy Trial) and the RENAAL
(Reduction of Endpoints in Non-insulin dependent diabetes mellitus
with the Angiotensin II Antagonist Losartan) study, which showed
beneficial effects of angiotensin II receptor blockers in patients with
type 2 diabetes mellitus (T2D) and kidney disease.2 Very recently,
sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown ren-
oprotective effects in several large outcome trials.3–6 SGLT2 inhibitor
treatment inhibits the reabsorption of glucose and sodium in the prox-
imal tubule of the kidney, resulting in glycosuria and the lowering of
blood glucose independently of the action of insulin, and can also
reduce body weight and blood pressure.7
The effects of SGLT2 inhibitors on kidney outcomes as novel treat-
ment options for diabetic kidney disease have not been well described
in regions outside of North America and Europe. Although previous
large randomized controlled trials including the EMPA-REG OUTCOME
trial (Empagliflozin, Cardiovascular Outcomes, and Mortality in Type
2 Diabetes), the CANVAS programme (CANagliflozin cardioVascular
Assessment Study), DECLARE-TIMI 58 (Dapagliflozin Effect on Cardio-
vascuLAR Events) and CREDENCE (Canagliflozin and Renal Event in
Diabetes with Established Nephropathy Clinical Evaluation) included
multiracial populations,4–6,8–10 only a minority of patients (12.7%–
21.0%) across these trials were recruited from Asian countries. Real-
world evidence on kidney outcomes and all-cause death associated with
SGLT2 inhibitors based on Asian data is also limited. The CVD-REAL
2 (Cardiovascular Events Associated With SGLT-2 Inhibitors Versus
Other Glucose-Lowering Drugs) study, a multinational retrospective
observational study, included most of the data from Asian countries
(the Republic of Korea, Japan and Singapore), but did not report on the
effect of SGLT2 inhibitors on renal outcomes.11 The CVD-REAL 3 (Kid-
ney outcomes associated with use of SGLT2 inhibitors in real-world
clinical practice) study recently published real-world evidence from the
European Union, Israel and Asia, including Japan and Taiwan. It demon-
strated that the initiation of SGLT2 inhibitors was associated with a
slower rate of kidney function decline and a lower risk of major kidney
events.12 However, only approximately 11% of the total study cohort
were from Asian countries. As several distinctive features are apparent
in pathogenetic factors for diabetes in Asian populations,13 it is impor-
tant to assess whether the benefits of SGLT2 inhibitors are applicable
across different ethnicities. The so-called “Asian phenotypes” in diabe-
tes include low body mass index (BMI); greater amount of body fat,
especially visceral adiposity; higher rate of central obesity and metabolic
syndrome; insufficient β-cell response in the setting of insulin resis-
tance; and higher risk of developing renal complications among other
inter-ethnic clinical differences.14 In the present study, we investigated
the effects of SGLT2 inhibitors on the risk of progression to ESRD and
all-cause mortality in a broad range of patients with T2D using a Korean
nationwide cohort.
2 | MATERIALS AND METHODS
2.1 | Data source and study population
This study used the National Health Insurance Service (NHIS) database,
which is government managed and includes patients' sociodemographic
information, use of inpatient and outpatient services, and pharmacy dis-
pensing claims. The NHIS is the only insurer providing regular health
checkup programmes to the public in the Republic of Korea. Those
enrolled in the NHIS are recommended to undergo health checkups at
least biannually. Patients with T2D who initiated an SGLT2 inhibitor or
any other glucose-lowering drug (oGLD) were identified, starting from
the date of first prescription, in a time window selected from the date
of the first SGLT2 inhibitor availability in this country until the last avail-
able data (from January 2014 to December 2017). Patients with known
type 1 diabetes and gestational diabetes were excluded. No other a
priori exclusion criteria were applied. We identified a total of 701 674
T2D patients who were new users of SGLT2 inhibitors or oGLDs and
who had clinical and laboratory data recorded at baseline, within a time
window of 30 days from the index date. Due to lack of data, we
excluded 193 431 patients who had not undergone a health checkup
within 4 years from the index date (Figure 1). Among the resulting
508 243 patients, those in the SGLT2 inhibitor category were defined
as new users of SGLT2 inhibitors (n = 101 582), and those in the cate-
gory of oGLD were defined as new users of oGLDs (n = 406 661). We
then excluded 3823 patients who had already been diagnosed with
ESRD and 9381 patients with missing data. Finally, 99 618 patients in
the SGLT2 inhibitor category and 395 421 in the oGLD category were
included for the final analysis. This study was conducted according to
the Declaration of Helsinki and approved by the Institutional Review
Board of The Catholic University of Korea (No. SC18ZES10158).
Because anonymized and deidentified information was used in the ana-
lyses, informed consent was not required.
2.2 | Measurements and definitions
Comorbidities were defined by a combination of medical history
(International Classification of Diseases [ICD]-10 code and self-reported
during health checkup questionnaires) and use of medication history for
the corresponding disease. The presence of hypertension was defined
as at least one claim per year under ICD-10 codes I10 or I11 and at
least one claim per year for the prescription of an anti-hypertensive
agent, or systolic/diastolic blood pressure ≥140/90 mmHg. The pres-
ence of dyslipidaemia was defined as at least one claim per year for the
prescription of antidyslipidaemic medication under ICD-10 code E78.
The presence of cardiovascular disease (CVD) was defined as at least
one claim per year under ICD-10 codes I20, I21, I22, I48, I50, G45, I60–
I66, or I70–I79. Blood samples for the measurement of serum glucose,
creatinine, total cholesterol, triglycerides, HDL cholesterol and LDL cho-
lesterol levels were drawn after fasting overnight. As the serum creati-
nine of NHIS health checkup was measured mainly by isotope dilution
mass spectrometry traceable Jaffe methods, not enzyme methods,
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estimated GFR was calculated using the abbreviated Modification of
Diet in Renal Disease formula: estimated glomerular filtration rate
(eGFR) = 175 × serum creatinine (mg/dL) – 1.154 × age (years) –
0.203 × (0.742 if female).15 The presence of proteinuria was defined as
having urinary protein ≥1+ on dipstick testing in fasting morning urine.
The presence of diabetic retinopathy was defined according to at least
one claim per year under ICD-10 code H36.0.
2.3 | Study outcomes and follow-up
The main outcomes for this study were newly diagnosed ESRD or all-
cause death. We defined incident ESRD using the combination of
ICD-10 codes (N18–N19, Z49, Z94.0, Z99.2) and initiation of renal
replacement therapy for 30 days or more, and/or kidney transplanta-
tion during hospitalization. The Korean Health Insurance Review and
Assessment Service reimburses all medical care expenses for dialysis.
Patients with ESRD are also registered as special medical aid benefi-
ciaries. Therefore, we could include each ESRD patient from the
whole population and analyse the data for all ESRD patients who
started dialysis or had an eGFR < 15 mL/min/1.73 m2. Patients with-
out ESRD or all-cause death during their follow-up periods were con-
sidered to have completed the study at the date of their death or at
the end of follow-up, whichever came first. The study population was
followed from baseline to the date of ESRD or all-cause death, or until
December 31, 2017, whichever came first.
2.4 | Statistical methods
Baseline characteristics are presented as means ± SD or n (%). The
incidence rates for the primary outcomes were calculated by dividing
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the number of incident cases by the total follow-up duration (patient-
years). The disease-free probability of primary outcomes was calcu-
lated using Kaplan–Meier curves, and a log-rank test was performed
to analyse differences between the groups. Hazard ratios (HRs) and
95% confidence intervals (CIs) for ESRD and all-cause death were cal-
culated using a Cox proportional hazards model for each category.
A non-parsimonious propensity score for initiating an SGLT2
inhibitor was developed for each individual episode of a new treat-
ment initiation. Variables that could potentially affect treatment
assignment or outcomes were selected: eGFR, age, sex, BMI, waist cir-
cumference, height, weight, presence of proteinuria, T2D duration,
fasting blood glucose, presence of diabetic retinopathy, prior CVD,
hypertension, blood pressure, dyslipidaemia, smoking, drinking, exer-
cise, income status, Charlson Comorbidity Index, insulin treatment,
glucagon-like peptide-1 receptor agonists, number of oGLDs, and
index date. The propensity matching was assessed by evaluating stan-
dardized differences of patient characteristics post-match. A signifi-
cant imbalance was considered to be present if a > 10% standardized
difference was present between the two groups after propensity
matching. An SAS (SAS Institute Inc., Cary, North Carolina) matching
macro, “%OneToManyMTCH,” was used for this matching. It allows
propensity-score matching from 1-to-1 to 1-to-N. We set a caliper for
nearest-neighbour matching within the first four to eight digits; for
example, two patients with propensity scores of 0.12345678 and
0.12347123 match on the first four digits (0.1234). The macro makes
the “best” matches first and the “next-best” matches next in a hierar-
chical sequence until no more matches can be made. If no patient in
the oGLD group has a propensity score that lies within a four-digit
width of a propensity score of a patient in the SGLT2 inhibitor group,
then that patient in the SGLT2 inhibitor group is left unmatched and
is not used in subsequent analyses.
The primary analysis used an intention-to-treat approach, in
which patients were followed from the start of an index treatment
until either occurrence of the first outcome event or the censoring
date (whichever was earlier), regardless of whether the index treat-
ment was discontinued. A sensitivity analysis was performed with
restriction of the follow-up period to 3 years because of the short
follow-up duration of the SGLT2 inhibitor group. Also, the analyses
for each outcome were conducted using an on-treatment approach, in
which follow-up was censored at discontinuation of the index treat-
ment. Statistical analyses were performed using SAS version 9.4, and
a P value <0.05 was considered to indicate significance.
3 | RESULTS
3.1 | Study population
Following propensity matching with 508 243 new SGLT2 inhibitor or
oGLD initiation episodes, a total of 90 032 new SGLT2 inhibitor or
oGLD users were identified with 45 016 in each treatment group
(Table 1). The distribution of specific SGLT2 inhibitors were
dapagliflozin 73.3%, empagliflozin 20.8% and ipragliflozin 6.0%,
respectively, and the mean follow-up period was 1.49 ± 0.85 years.
Patient characteristics were well balanced between the two groups.
The mean age was 58 years and 43% were women. The mean BMI
was 26 kg/m2, and the mean duration of diabetes was 5.64 years and
5.87 years in the SGLT2 inhibitor and oGLD groups, respectively.
Among the study population, 30% of patients had diabetic retinopa-
thy. The mean eGFR values of the patients in the SGLT2 inhibitor and
oGLD groups were 89.02 ± 25.6 mL/min/1.73 m2 and 89.44 ±29.18
mL/min/1.73 m2, respectively, and 8% of patients had proteinuria.
3.2 | Renal outcomes: SGLT2 inhibitors versus
oGLDs
During 67 133 person-years of follow-up, there were 167 cases of
incident ESRD, of which 53 occurred in the SGLT2 inhibitor group
(incidence rate 0.79 per 1000 patient-years) and 114 in the oGLD
group (incidence rate 1.70 per 1000 patient-years). Initiation of
SGLT2 inhibitors versus oGLDs was associated with a lower risk of
incident ESRD (HR 0.47, 95% CI 0.34–0.65; Table 2). The incidence
rate of ESRD showed a substantial decrease in the SGLT2 inhibitor
group compared with the oGLD group in the Kaplan–Meier curve
(P values by log-rank <0.0001; Figure 2A). In a subgroup analysis by
eGFR, initiation of SGLT2 inhibitors versus oGLDs was associated
with a lower risk of progression to ESRD among patients with eGFR
60 to 90 mL/min/1.73 m2 or less than 60 mL/min/1.73 m2 (HR 0.39,
95% CI 0.21–0.75 and HR 0.39, 95% CI 0.25–0.63, respectively). The
results were consistent regardless of the presence or absence of pro-
teinuria. Furthermore, a sensitivity analysis was performed to adjust
for the differences in the person-years of follow-up and periods
between the two groups; HR trends for ESRD were similar to the
3-year follow-up results (Table S1 and Figure S1) and those of the on-
treatment analysis (Table S2 and Figure S2).
3.3 | All-cause death: SGLT2 inhibitors versus
oGLDs
During 67 183 person-years of follow-up, there were 1070 all-cause
deaths, of which 484 occurred in the SGLT2 inhibitor group (incidence
rate 7.20 per 1000 patient-years) and 586 in the oGLD group (inci-
dence rate 8.73 per 1000 patient-years). Initiation of SGLT2 inhibitors
versus oGLDs was associated with a lower risk of all-cause death
(HR 0.82, 95% CI 0.73–0.93; Table 2). The incidence rate of all-cause
death showed a substantial decrease in the SGLT2 inhibitor group
compared with the oGLD group in the Kaplan–Meier curve (P values
by log-rank = 0.0016; Figure 2B). The results were consistent across
the baseline eGFR and regardless of the presence or absence of pro-
teinuria (Table 2). In addition, a sensitivity analysis was performed to
adjust for the differences in the person-years of follow-up and periods
between the two groups; HR trends for all-cause death were similar
to the 3-year follow-up results (Table S1 and Figure S1) and those of
the on-treatment analysis (Table S2 and Figure S2).
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TABLE 1 Baseline characteristic of patients using sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs in the total
study population
SGLT2 inhibitors oGLDs
(n = 45 016) (n = 45 016) ASD
Age, years 58.25 ± 10.87 57.88 ± 10.38 0.0343
Sex, male, n (%) 25 832 (57.38) 25 949 (57.64) 0.0053
BMI, kg/m2 26.38 ± 3.76 26.59 ± 3.96 0.0534
Waist circumference, cm 88.12 ± 9.31 88.55 ± 9.67 0.0453
Height, cm 163.45 ± 9.1 163.62 ± 9.43 0.0185
Weight, kg 70.77 ± 13.24 71.45 ± 13.7 0.0507
eGFR, mL/min/1.73m2 89.02 ± 25.6 89.44 ± 29.18 0.0152
eGFR, n (%)
<60 mL/min/1.73m2 3261 (7.24) 3583 (7.96) 0.0277
60–90 mL/min/1.73m2 21 527 (47.82) 20 905 (46.44)
≥90 mL/min/1.73m2 20 228 (44.94) 20 528 (45.6)
Presence of proteinuria, n (%) 3719 (8.26) 3827 (8.5) 0.0087
eGFR/proteinuria, n (%) 0.0400
<60 mL/min/1.73m2/absent 2751 (6.11) 2864 (6.36)
<60 mL/min/1.73m2/present 510 (1.13) 719 (1.6)
≥60 mL/min/1.73m2/absent 38 546 (85.63) 38 325 (85.14)
≥60 mL/min/1.73m2/present 3209 (7.13) 3108 (6.9)
T2D duration, years 6 (1–10) 6 (2–10) 0.0574
Glucose, mmol/L 8.76 ± 3.13 8.85 ± 3.44 0.0299
Diabetic retinopathy, n (%) 13 933 (30.95) 13 494 (29.98) 0.0212
Prior cardiovascular diease, n (%)
Myocardial infarction 1527 (3.39) 1534 (3.41) 0.0009
Unstable angina 2482 (5.51) 2519 (5.6) 0.0036
Angina pectoris 7838 (17.41) 7885 (17.52) 0.0028
Heart failure 3284 (7.3) 3477 (7.72) 0.0163
Atrial fibrilation 1171 (2.6) 1246 (2.77) 0.0103
Stroke 5292 (11.76) 5167 (11.48) 0.0087
Hypertension, n (%) 25 706 (57.1) 25 545 (56.75) 0.0072
Systolic blood pressure, mmHg 127.86 ± 14.93 127.94 ± 14.99 0.0057
Diastolic blood pressure, mmHg 78.53 ± 9.94 78.65 ± 10.07 0.0118
Dyslipidaemia, n (%) 31 455 (69.88) 31 619 (70.24) 0.0080
Total cholesterol, mmol/L 4.84 ± 1.36 4.87 ± 1.26 0.0190
Triglycerides, mmol/L 1.68 (1.68–1.69) 1.71 (1.70–1.72) 0.0215
HDL cholesterol, mmol/L 1.28 ± 0.35 1.28 ± 0.33 0.0000
LDL cholesterol, mmol/L 2.68 ± 1.2 2.7 ± 1.15 0.0140
Smoking status, n (%) 0.0050
Non-smoker 24 426 (54.26) 24 313 (54.01)
Ex-smoker 9363 (20.8) 9374 (20.82)
Current smoker 11 227 (24.94) 11 329 (25.17)
Heavy drinker, n (%) 4137 (9.19) 4268 (9.48) 0.0100
Regular exercise, n (%) 9135 (20.29) 8884 (19.74) 0.0139
Income: low 25%, n (%) 10 470 (23.26) 10 546 (23.43) 0.0040
ACE inhibitors, n (%) 1300 (2.89) 1564 (3.47) 0.0334
ARBs, n (%) 20 863 (46.35) 21 775 (48.37) 0.0406
(Continues)
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3.4 | Subgroup analysis
To evaluate the effect of modifiers on the associations between
SGLT2 inhibitors and outcomes, we conducted a stratified analysis
using several factors including age, sex, BMI, abdominal obesity, dia-
betic retinopathy, hypertension and prior CVD (Table 3). The associ-
ation of SGLT2 inhibitors versus oGLDs with lowering incident
ESRD risk was stronger in obese patients (HR 0.27, 95% CI
0.16–0.44) than in non-obese patients (HR 0.80, 95% CI
0.51–1.25; P for interaction = 0.002). For all-cause death, the asso-
ciation was stronger in younger, female and obese patients and
subgroups without hypertension or prior CVD. For example, the
association of SGLT2 inhibitors versus oGLDs with lower all-cause
deaths risk was stronger in female patients (HR 0.64, 95% CI
0.52–0.79) than in male patients (HR 0.94, 95% CI 0.81–1.09; P
for interaction = 0.001).
TABLE 1 (Continued)
SGLT2 inhibitors oGLDs
(n = 45 016) (n = 45 016) ASD
Loop diuretics, n (%) 2333 (5.18) 2539 (5.64) 0.0202
Thiazide diuretics, n (%) 3095 (6.88) 3374 (7.5) 0.0240
Statins, n (%) 29 042 (64.51) 30 404 (67.54) 0.0639
Beta blockers, n (%) 6960 (15.46) 7478 (16.61) 0.0313
Aldosterone, n (%) 914 (2.03) 1160 (2.58) 0.0364
Index year, n (%) 0.0000
2014 1621 (3.6) 1621 (3.6)
2015 9621 (21.37) 9621 (21.37)
2016 14 159 (31.45) 14 159 (31.45)
2017 19 615 (43.57) 19 615 (43.57)
Charlson comorbidity index 2.7 ± 1.95 2.68 ± 2.09 0.0074
Note: Values are mean ± SD or median value (interquartile range), unless otherwise indicated. Presence of proteinuria was defined as having urinary
protein ≥1+ dipstick testing in fasting morning urine.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; ASD, absolute standardized difference; eGFR, estimated
glomerular filtration rate; oGLD, other glucose-lowering drug; SGLT2, sodium-glucose co-transporter-2; T2D, type 2 diabetes.









































































P < 0.0001 by log-rank
P = 0.0015 by log-rank
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F IGURE 2 Kaplan–Meier estimates of the incidence of end-stage renal disease (ESRD; left) and all-cause death (right) in patients using
sodium-glucose co-transporter-2 inhibitors (SGLT2 inhibitors; red) versus other glucose lowering drugs (oGLDs; black)
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4 | DISCUSSION
The results of the present study suggest that initiation of SGLT2 inhi-
bition as compared with oGLD treatment had a statistically significant
and clinically relevant association with lower risk of ESRD and all-
cause death in patients with T2D in a general population of patients
with T2D in Korea, evidence that is complementary to and consistent
with what has been already observed in previous randomized con-
trolled trials for this class of compounds. T2D patients in the SGLT2
inhibitor group had a significantly lower risk of incident ESRD and all-
cause death compared with patients in the oGLD group. Although
ESRD and all-cause death are rare events in the general population
and would be unexpected in those with near-normal baseline eGFR,
due to the large sample size, we were able to accrue a substantial
number of these events to demonstrate that initiation of SGLT2
inhibitors was significantly associated with a lower risk of these out-
comes compared with oGLDs. Recent randomized clinical trials dem-
onstrated a lower risk of renal composite events and all-cause death
with SGLT2 inhibitors in T2D patients; however, results showing the
beneficial effect of SGLT2 inhibitors on ESRD and all-cause death in
routine clinical care are scarce.3,4,6 The present report complements
the results from the CVD REAL 3 study,12 providing further evidence
from an Asian patient population from the nationwide Korean registry
including 80 000 patients with T2D and with 67 000 patient-years
of follow-up.
It is noteworthy that the present study assessed the effect of
SGLT2 inhibition on risk of incident ESRD and all-cause death strati-
fied by renal function including eGFR and presence of proteinuria,
and the overall results were consistent across these subgroups. The
patients with eGFR 60 to 90 mL/min/1.73 m2 or <60 mL/
min/1.73 m2 were observed to have a lower risk of progression to
ESRD with SGLT2 inhibitors versus oGLDs, whereas those with eGFR
≥90 mL/min/1.73 m2 were not. We interpret the results with caution
because the discordance may be dependent on how renal events
were defined and because of the relatively short follow-up period for
incident ESRD in these real-world data. There were few ESRD events
in the subgroup with eGFR ≥90 mL/min/1.73 m2, which had a rela-
tively low risk for ESRD development considering the clinical natural
course of chronic kidney disease progression. CREDENCE is the only
published randomized controlled trial to examine a population with
diabetic kidney disease, especially in terms of the outcomes of eGFR
subgroups. The CREDENCE study population had more advanced
chronic kidney disease; their mean eGFR was 56.2 mL/min/1.73 m2
and 99% of the patients had an microalbuminuria level > 30 mg/g and
a mean T2D duration of 15.8 years, while the population in our real-
world study had an eGFR level of 89.2 mL/min/1.73m2, an 8% rate of
proteinuria, and a mean T2D duration of 6 years. In CREDENCE,
patients in the eGFR 45 to 60 mL/min/1.73 m2 subgroup had an HR
of 0.47 (95% CI 0.31–0.72) for the risk of a renal composite outcome.
Interestingly, the results were comparable with our real-world data, in
which the HR for incident ESRD was 0.39 (95% CI 0.25–0.63) in the
subgroup with an eGFR level < 60 mL/min/1.73 m2. As for all-cause
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were observed to have a lower risk of all-cause deaths with SGLT2
inhibitors versus oGLDs, whereas those with eGFR <60 mL/
min/1.73 m2 were not. However, it is difficult to draw any firm con-
clusions around this segment because there were relatively low num-
bers of patients and events in the subgroup with eGFR < 60 mL/
min/1.73 m2, and the P for interaction was not statistically significant.
The glucose-lowering effects of SGLT2 inhibitors decrease as
renal function declines, which raises the possibility that the magnitude
of benefit on glycaemia might be somewhat attenuated in patients
with lower baseline eGFR levels mediated by reduced available neph-
ron mass and diminished glucose reabsorption capacity.16–18 How-
ever, SGLT2 inhibitors consistently decrease the risk of incident ESRD
regardless of baseline eGFR, which indicates that the effects of SGLT2
inhibitors are partly mediated via non glucosuric-dependent
mechanisms.19–21 Although pleiotropic effects of SGLT2 inhibitors
have been inferred, improvement of glycaemic control, lowering of
systemic blood pressure and intraglomerular pressure, reduction in
albuminuria, and amelioration of volume overload are all plausible pro-
tective mechanisms with the possibility of a more comprehensive
interactive effect.5,22,23 SGLT2 inhibitors induce natriuresis, which
activates tubulo-glomerular feedback, reducing glomerular hyperten-
sion and hyperfiltration to limit kidney damage. The proposal of the
haemodynamic mechanism of SGLT2 inhibitors is supported by the
transient decline of eGFR after initiation of SGLT2 inhibitors followed
by spontaneous recovery.8 In this regard, the renoprotective mecha-
nism of SGLT2 inhibitors can be linked in part to the renin-angiotensin
system blockade-induced improvement of diabetic nephropathy,
mainly by lowering intraglomerular pressure.24 Furthermore, the
impact of SGLT2 inhibitors on the risk of ESRD differed according to
BMI in the present study, although a few cases of incident ESRD
developed. Thus, obese patients (BMI ≥25 kg/m2) experienced a
greater benefit of lowering the risk of ESRD compared to those with
BMI <25 kg/m2. These findings suggest that the renal benefits of
SGLT2 inhibitors may be amplified especially in obesity-associated
glomerular hyperfiltration in patients with T2D, although this issue
warrants further investigation.25 Another proposed mechanism of
SGLT2 inhibitors is mediated by metabolic effects. SGLT2 inhibitors
appear to decrease energy demand by reducing sodium transport and
ameliorate cellular stress by enhancing AMPK/SIRT1, eventually lead-
ing to protection from functional and structural tubular injury by dia-
betes.26 In addition, SGLT2 inhibitors could limit the activity of
transforming growth factor β1, a known intrarenal cytokine associated
with progressive kidney failure and lowering of the expression of
inflammatory molecules.27,28
The findings of the present study should be interpreted in the
context of several potential limitations. First, due to the observational
nature of the study, we cannot exclude the possibility of unmeasured
confounding factors, which cannot be overcome by propensity-score
matching. Confounders such as socio-economic factors, or metabolic
variables that were not measured after baseline in this study, could
have affected both the choice of glucose-lowering medication and the
outcomes. A novel drug may also be more readily prescribed to
healthier patients, and those with relatively uncontrolled diabetes in
the early post-marketing period in the real world.29 Second, an immor-
tal time bias can arise if some proportion of the follow-up time is
excluded or misclassified. Third, renal function, including eGFR and
the presence of proteinuria, was measured only at enrolment; there-
fore, subtle changes in renal function could not be included in the ana-
lyses. The presence of proteinuria was evaluated using a semi-
quantitative dipstick test, which has an approximately 30% false-
negative rate for microalbuminuria. Fourth, the follow-up period was
relatively short considering the clinical course of renal outcomes in
patients with T2D, and there was no information about the precise
cause of ESRD or mortality, or uric acid levels (which can be reduced
by SGLT2 inhibitors).30 Finally, these results have a limited generaliz-
ability to other (non-Korean) populations.
The strengths of the present study include a large sample size,
which encompassed the entire South Korean population, and the
inclusion of several types of subgroup analyses, especially focused on
the stratified renal function with eGFR and presence of proteinuria.
These observational findings can be considered as complementary to
the other large renal outcome trials of SGLT2 inhibitors including the
CREDENCE trial,4 the DAPA-CKD31,32 and ongoing EMPA-Kidney tri-
als.33 Nevertheless, the vast majority of participants in these trials
were recruited in the United States and Europe, thereby restricting
the generalizability of the results. The present study reflects the utili-
zation of SGLT2 inhibitors in clinical practice in an East Asian popula-
tion. Thus, our findings suggest that the renal benefits of SGLT2
inhibitors may extend across different ethnic backgrounds.
In conclusion, the results of the present study suggest that
SGLT2 inhibition had a statistically significant and clinically relevant
association with lower risk of ESRD and all-cause death in patients
with T2D in a general Korean population of patients with T2D, evi-
dence that is complementary to and consistent with what has been
already observed in previous randomized controlled trials for this
class of compounds. This benefit was consistent across the spectrum
of eGFR at baseline. Findings from ongoing SGLT2 inhibitor trials
will provide further evidence regarding how best to integrate these
therapies into the care of patients with chronic kidney disease to
improve outcomes. Moreover, longer-duration studies in patients
with renal dysfunction will ultimately inform the long-term safety of
SGLT2 inhibitor use.
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